NCT01203111 - Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

INSULIN GLARGINE

Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime

DRUG

INSULIN GLULISINE

Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal

Trial Locations (10)

Administrative office, Algiers

Administrative office, São Paulo

Administrative office, Netanya

Administrative office, Beirut

Administrative office, Col. Coyoacan

Administrative office, Casablanca

Administrative office, Lima

Administrative office, Jeddah

Administrative office, Dubai

Administrative office, Caracas